



**INTERNATIONAL KIDNEY CANCER  
SYMPOSIUM: EUROPE**

# **Symposium Guide**

**21–22 APRIL 2023 • EDINBURGH, SCOTLAND**



## TABLE OF CONTENTS

Welcome Letter from the KCA President and CEO	3
Welcome Letter from Convention Edinburgh	4
About the Kidney Cancer Association	5
Continuing Medical Education Information	7
Program Agenda	13
Poster Listings	23
Supporters and Exhibitors	28

The Kidney Cancer Association (KCA) presents the International Kidney Cancer Symposium: Europe, an opportunity for physicians, researchers, academics, and industry professionals from across the region to join and exchange ideas that will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure.

IKCS meetings are a front-row seat to emerging research, noteworthy breakthroughs, current challenges, and promising treatments in kidney cancer. The community feel promotes learning, networking, and unparalleled opportunities for mentorship and collaboration.

Join the Conversation on Social Media: We encourage all attendees to share their IKCS: Europe experience on social media. Make sure to add the hashtag **#IKCSEU23** and tag **@KidneyCancer** in all your posts!



### WIFI ACCESS

**NETWORK:** IKCSEU23    **PASSWORD:** EXELIXIS

# WELCOME LETTER

FROM THE KCA PRESIDENT AND CEO

I am thrilled to have you join the KCA in historic Edinburgh, Scotland, for an exciting program featuring the best in kidney cancer research and discovery.

This year, we have a number of outstanding academic leaders lending their time and expertise for our edification. Dr. Robert Jones of the Beaston West of Scotland Cancer Centre will deliver the keynote lecture entitled “Scotland and Kidney Cancer.” Dr. Arnaud Méjean from the Université Paris Descartes will receive the John Fitzpatrick Award in Urology, and Dr. Sarah Psutka from the University of Washington will receive the Christopher G. Wood Rising Star Award. A lively WoodFire® session will be an exciting finish to our two days together!

Make sure to spend time in the exhibits area, network with fellow attendees at our various social hours, and contribute to the conversation online using the hashtag #IKCSEU23. We are pleased to offer continuing medical education credits, which you can collect online after the meeting.

Our thanks to all those who worked diligently to bring us a dynamic event including:

- Presenters and panelists
- Sponsors, exhibitors, and attendees
- Our Scientific Program Planning Committee: Michael Staehler, MD, PhD (Co-Chair); Gabriel Malouf, MD, PhD (Co-Chair); Ignacio Duran, MD, PhD; Annika Fendler, PhD; Lars Lund, MD, DMSci; Lisa Pickering, MD, PhD; and Cristina Suarez, MD, PhD.

We are in an exciting phase of research and discovery for kidney cancer. Your contributions to this journey and service to patients and families are an inspiration. We at the KCA are proud to support you and help forge new paths to unlocking the cure!

Sincerely,



**Gretchen E. Vaughan**

*President and CEO, Kidney Cancer Association*

*#UnstoppableTogether*

# WELCOME LETTER FROM CONVENTION EDINBURGH

Convention Edinburgh  
150 Morrison Street  
Edinburgh

On behalf of the Convention Edinburgh Team,

It is with great pleasure that we welcome the International Kidney Cancer Symposium (IKCS): Europe delegates to Edinburgh, our beautiful city.



Edinburgh's long history of medical innovation and discovery is well documented and recognised. Dating back to the Scottish Enlightenment, this innovative capital city has and continues to be at the heart of medicine and health. The city has always attracted great thinkers, scientists, and innovators, eager to exchange knowledge, debate and learn from each other. This continues in Edinburgh to this day.

Home to four world-leading universities, a wealth of research organisations and charities who are all working to further health management and lifesaving treatments. On the outskirts of the city, the Edinburgh BioQuarter is a key destination for health innovation focused on life sciences, data-driven innovation, medical teaching, research, and healthcare delivery. All together this creates a perfect environment, where your international colleagues across the sector can come together to further their knowledge and see for themselves the latest medical advances.

This vibrant capital city seamlessly blends an architecturally stunning backdrop with modern developments, offering your delegates a host of traditional, dynamic, and unique attractions, restaurants and activities. The city centre is compact in size, providing 49% green space; allowing delegates to explore by foot, city bike, tour bus or public transport. With an ideal mix of culture, shopping, dining, music, heritage, and leisure activities; IKCS attendees will be spoilt for choice.

Your chosen venue, the Edinburgh International Conference Centre is situated in the heart of the city and is one of the world's outstanding venues for conferences. The purpose-built centre offers the very best facilities which your delegates will enjoy.

We very much look forward to hosting you in Edinburgh in April 2023.

Yours sincerely,

**Amanda Wrathall**

*Head of Convention Edinburgh*

*amandaw@conventionedinburgh.com*

# Recent advances in the management of RCC

**Saturday,  
22 April 2023**  
12:30 – 13:30 (GMT)

Edinburgh International  
Conference Centre  
Room: Lammermuir 1 & 2  
Edinburgh, UK

**Faculty:** Prof. Viktor Grünwald (Germany)  
Prof. Thomas Powles (UK)



MSD has funded the logistics for EIKCS 2023, but has had no input into the content of the conference. This promotional symposium has been organized and fully funded by MSD. MSD products will be discussed. The target audience is healthcare professionals.

This program is not intended for healthcare professionals who practice in, are licensed to practice in, or reside in the U.S., its territories, or Puerto Rico.

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

GB-RCC-00607 Date of Preparation: April 2023

Prescribing information and adverse event reporting will be available at this meeting.

## ABOUT THE KCA

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

**OUR VISION** is to be the universal leader in finding the cure for kidney cancer.

**OUR MISSION** is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

## MAIL DONATIONS TO:

Please send donations to our secure lock-box:

**Kidney Cancer Association**

**PO Box 676226, Dallas, TX 75267-6226**

USA: (800) 850-9132

**INTERNATIONAL:** +1 847 332 1051

**EMAIL:** [office@kidneycancer.org](mailto:office@kidneycancer.org)

*“One of the Association’s most important contributions is its support of the physicians, nurses, and cancer care team members who care for patients with kidney cancer. Through our educational activities, we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world’s leading technology and treatment options.”*

**Gretchen E. Vaughan**

*President and CEO, Kidney Cancer Association*

---

## KCA STAFF

Gretchen E. Vaughan  
President & CEO  
Houston, Texas

Kendall Monroe, MPA  
Chief Advancement Officer  
Houston, Texas

Salvatore La Rosa, PhD  
Chief Scientific Officer  
New York, New York

LaRanda Burke  
Chief Financial & Operating Officer  
Houston, Texas

Susan Alanis  
Director of Gift Operations  
Houston, Texas

Christina Bargas  
Manager of Events and Education  
Denver, Colorado

Ryan Cerezo  
Development Manager  
Lathrop, California

Radha Chitale  
Senior Director of Communications  
Washington, D.C.

Rosemary Chustak  
Patient Liaison  
Milwaukee, Wisconsin

Amy Marbaugh  
Director of Patient Programs  
Cleveland, Ohio

Melissa Lopez  
Gift Operations Associate  
Houston, Texas

Emely Rodriguez  
Accountant  
Houston, Texas

Stephanie Shirley  
Director of Advancement Services  
Harrisburg, Pennsylvania

Jeanette Stensgaard, MBA  
Senior Director of Events and Education  
Aurora, Colorado

Sarah Tuck  
Program Manager  
Langhorne, Pennsylvania

Angela Washington  
Director of Operations  
Houston, Texas

Christine Kelly-Weaver  
Executive Assistant to the President/  
CEO/ Office Manager  
Houston, Texas

Maggie Valdes  
Manager of Corporate Partnerships  
Houston, Texas

---

## BOARD OF DIRECTORS

Bradley C. Leibovich, MD, *Chairperson*

Laurence Albiges, MD, PhD

Mahul B. Amin, MD

Ronald M. Bukowski, MD

Noah Buntman, *Treasurer*

Tessa Churchill, MD, MBA

Craig DePriester

Daniel J. George, MD

Jamie Graves

Ryan Natzke

David Perry, Esq.

Shelley Robson

Brian Shuch, MD

Joel Stern, *Secretary*

Gretchen E. Vaughan, *President and CEO*

Laura Wood, RN, MSN, OCN

Ruben Ybarra

---

## MEDICAL STEERING COMMITTEE

Daniel J. George, MD, *Chairperson*

Laurence Albiges

Axel Bex, MD, PhD

Ronald M. Bukowski, MD (*Emeritus*)

Matthew Campbell, MD, MS

Jose A. Karam, MD, FACS

Chung-Han Lee, MD, PhD

Bradley C. Leibovich, MD

Pavlos Msaouel, MD, PhD

Sumanta Pal, MD

Thomas Powles, MBBS, MRCP, MD

Sarah Psutka, MD

Brian Rini, MD, Vice Chair

Eric Singer, MD, MA, MS, FACS, FASCO

Walter M. Stadler, MD, FACP (*Emeritus*)

Nizar M. Tannir, MD, FACP (*Emeritus*)

Tian Zhang, MD

---

## CLINICAL ADVISORY BOARD

Laura S. Wood, RN, MSN, OCN (*Co-Chair*)

Nancy Moldawer, RN, MSN (*Co-Chair*)

Nancy Ainslie, RN, BSN

Julia Batten, APRN, MSN, MPH

Patricia Fischer RN, MSN, OCN

Jan Jackson, RN

Zita Lim, PA-C

Kathryn Nelson, RN

Virginia J. Seery, MSN, RN, ANP-BC

Julia Stevens, PharmD, BCOP

Kiran Virdee, RN, BSN, CCRN

Emily Wang, PharmD, BCOP

---

## PATIENT & CAREGIVER ADVISORY COUNCIL

Ryan Natzke (*Chair*)

Kathleen Campbell

Steven Edwards

John Ferrell

Bruce Hill

Susan Hill

Vineeta Hiranandani

Ritchie Johnson

Benjamin Lundin

Deb Maskens

Marissa Willis

Salima Witt

Peggy Zuckerman

# CONTINUING MEDICAL EDUCATION INFORMATION

Jointly provided by The France Foundation and The Kidney Cancer Association.



## TARGET AUDIENCE

This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

## STATEMENT OF NEED

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, and researchers to help promote learning and collaboration for advancement in the renal cancer space.

## EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

- Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
- Identify the novel approaches to non-clear RCC patient management
- Understand the role of the tumor microenvironment in kidney cancer
- Discuss how to design biomarker driven clinical trials in kidney cancer

## ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the Kidney Cancer Association. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



## PHYSICIAN CREDIT DESIGNATION

The France Foundation designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



The 2023 IKCS: Europe - International Kidney Cancer Symposium, Edinburgh, United Kingdom, 21/04/2023-22/04/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

All other healthcare professionals completing this course will be issued a statement of participation.

## **METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT**

1. Review the activity objectives and CME/CE information.
2. Participate in the CME/CE activity.
3. Go to the website: [ikcseu2023.eventscribe.net](http://ikcseu2023.eventscribe.net) and log in using your email address (the same one used to register for the meeting) and your Access Key. Click the CME Information tile on the homepage or click the CME and Evaluation link from the left-hand navigation menu. Review the instructions and click the link to complete the meeting evaluation and download a certificate.
4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

## **DISCLOSURE POLICY**

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF And KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA see to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

## **ACTIVITY STAFF DISCLOSURES**

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose. The planners, reviewers, editors, staff, CME committee, or other members at The Kidney Cancer Association who control content have no relevant financial relationships to disclose.

## **PLANNER AND FACULTY DISCLOSURES**

View Planner and Faculty Disclosures online by logging into the platform, [ikcseu2023.eventscribe.net](https://ikcseu2023.eventscribe.net), and clicking CME information.

### **DISCLOSURE OF UNLABELED USE**

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/ or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

### **DISCLAIMER**


The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the Kidney Cancer Association assume no liability for the information herein. Note: Missing disclosures were not submitted in time for printing. Their disclosures will be available during their session talks.

### **SOURCES OF FUNDING**

Funding sources supporting this conference include the following:

- Participants' registration fees
- Exhibition booths during the event

Strong alone.  
Unstoppable  
together.®





# STELLAR 304

## TRIAL SITES ARE EXPANDING

Phase 3 Randomized, Open-Label Study of Zanzalintinib (XL092) With Nivolumab vs Sunitinib in Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC)

### KEY CRITERIA FOR nccRCC PATIENTS INCLUDE

- Unresectable, advanced, or metastatic nccRCC (papillary, unclassified, and translocation subtypes); sarcomatoid features allowed
- Measurable disease
- No prior systemic anticancer therapy for unresectable locally advanced or metastatic nccRCC

Learn more at [clinicaltrials.gov/ct2/show/NCT05678673](https://clinicaltrials.gov/ct2/show/NCT05678673)  
 or contact Exelixis Medical Information at  
**1-888-EXELIXIS (1-888-393-5494), 1-303-389-1847,**  
 or [medinfo@exelixis.com](mailto:medinfo@exelixis.com).

THE COMBINATION OF ZANZALINTINIB (XL092) AND NIVOLUMAB IS NOT APPROVED FOR THE USE UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.




© 2023 Exelixis\_STELLAR-304\_HCP Print Ad\_v1\_20Mar2023



## Seeing cancer from every angle.

We are proud to be at the forefront of innovative medicine that's helping reshape how cancer is treated, improving long-term survival and giving patients more time with the people they love.

That's the touch that **transforms**.



Transforming patients' lives through science™

We're proud to support the International Kidney Cancer Symposium (IKCS) 2023

[bms.com/gb](https://bms.com/gb)

© 2023 Bristol-Myers Squibb Company. All rights reserved. ONC-GB-2300120 | MARCH 2023

## SPONSORED SYMPOSIA

### Recent Advances in the Management of Renal Cell Carcinoma

SATURDAY, 22 APRIL 2023

12:30-13:30

LAMMERMUIR 1&2

Sponsored by Merck, Sharp & Dohme



KidneyCancerAssociation®

SAVE THE DATE

# Upcoming International Kidney Cancer Symposia



**2023 IKCS: NORTH AMERICA**

**November 10–11, 2023**

Nashville, Tennessee • In-person event only



**2024 IKCS: EUROPE**

**19–20 April 2024**

Sitges, Spain • In-person event only

# Program Agenda • Thursday, 20 April 2023

14:00–18:00	<b>Registration Open</b> BOTTOM OF ESCALATOR	
14:45–16:45	<b>Think Tank (by invitation only)</b> Sponsored by Eisai LENNOX 2	Lisa Pickering, MD, PhD <i>The Royal Marsden NHS Foundation Trust</i>
17:00–18:30	<b>Young Investigators Session</b> Sponsored by Pfizer LENNOX 2	Ignacio Duran, MD PhD <i>Medical Oncology Dept, Hospital Universitario Marques de Valdecilla</i>
	<b>Pfizer Welcome</b>	Lauren Meehan Machos, MPH <i>Pfizer</i>
	<b>Academic Opportunities</b>	Michael B. Atkins, MD <i>Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA</i>
	<b>FDA and Regulatory Opportunities</b>	Nizar M. Tannir, MD FACP <i>University of Texas MD Anderson Cancer Center</i>
	<b>Basic Science Opportunities</b>	Annika Fendler, PhD <i>Charité - University Hospital</i>
	<b>Industry Opportunities</b>	Markus Wagner, MSD <i>MSD Sharp &amp; Dohme</i>
	<b>Long-Term Industry Opportunities/Experiences</b>	Lauren Meehan Machos, MPH <i>Pfizer</i>
	<b>Panel Discussion</b>	All Speakers
	<b>Session Wrap Up</b>	

## Program Agenda • Friday, 21 April 2023

8:30–10:00	<b>Welcome Session and Session 1: Challenges in Surgical Decision Making</b> <b>LENNOX 3</b>	Lars Lund, MD, PhD <i>University of Southern Denmark</i>  Bradley C. Leibovich, MD <i>Mayo Clinic</i>
	<b>Welcome Address Speaker</b>	Bradley C. Leibovich, MD <i>Mayo Clinic</i>
	<b>Treatment Options for Clinical TI A Renal Masses A: Introduction of Active Surveillance vs. Therapy</b>	Sarah Psutka, MD, MS <i>University of Washington</i>
	<b>Treatment Options for Clinical TI A Renal Masses B: Surgical Options For Localized Disease</b>	Pernilla Sundqvist, Assistant Prof, MD, FEBU <i>Department of Urology, University Hospital Örebro</i>
	<b>Treatment Options for Clinical TI A Renal Masses C: Ablation Techniques For Localized RCC</b>	Karim Bensalah <i>Centre Hospitalier Universitaire de Rennes</i>
	<b>Neoadjuvant Therapy— An Update</b>	Grant Stewart, MD, PhD <i>University of Cambridge</i>
	<b>Risk of Recurrence, Classification Systems and Pathological Background</b>	Axel Bex, MD, PhD <i>The Netherlands Cancer Institute</i>
	<b>Results from Adjuvant Trials: How to Select Patients and Therapies</b>	Viktor Gruenwald, MD PhD <i>Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology and Clinical for Urology, Essen, Germany</i>
	<b>Cytoreductive Nephrectomy in Metastatic Disease: Who, How, When?</b>	Arnaud Mejean, MD, PhD, HEGP, APHP <i>Université Paris-Centre</i>
	<b>Session 1 Q&amp;A</b>	
10:00–10:15	<b>Break</b> <b>LENNOX 1</b>	

## Program Agenda • Friday, 21 April 2023

10:15–11:30	<b>Session 2: Understanding Renal Cell Carcinoma</b> <b>LENNOX 3</b>	Samra Turajlic, PhD, MBBS, MRCP <i>The Francis Crick Institute/The Royal Marsden Hospital</i>  Elizabeth (Lisa) Henske, MD <i>Brigham and Women's Hospital, Harvard Medical School</i>
	<b>WHO Pathological Classification: Present and Future</b>	Ferran Algaba Arrea, PhD, MD <i>Fundacio Puigvert, Universitat Autònoma de Barcelona-Spain</i>
	<b>Artificial Intelligence and Digital Pathology- New Tools in RCC for Diagnosis and Precision Oncology</b>	Payal Kapur, MD <i>University of Texas Southwestern</i>
	<b>Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in RCC (HCRN GU16-260): Correlative Results</b>	Michael B. Atkins, MD <i>Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.</i>
	<b>Epigenetic Regulation by PBRM1 in ccRCC</b>	Jessica Downs, PhD <i>The Institute of Cancer Research</i>
	<b>Non-Clear Cell RCC: From Chromophobe to Translocation and Beyond</b>	Elizabeth (Lisa) Henske, MD <i>Brigham and Women's Hospital, Harvard Medical School</i>
	<b>Sarcomatoid and Rhadoid De-Differentiation in Renal Cell Carcinoma and Clinical Implications</b>	Bradley C. Leibovich, MD <i>Mayo Clinic</i>
	<b>Session 2 Q&amp;A</b>	
11:30–11:45	<b>Keynote 1: Scotland and Kidney Cancer</b> <b>LENNOX 3</b>	Robert Jones, MD, PhD <i>University of Glasgow</i>



## Program Agenda • Friday, 21 April 2023

11:45–12:45	<b>Session 3: Caring for the Whole Patient: Non-Clinical Considerations</b> <b>LENNOX 3</b>	Michael D. Staehler, MD, PhD <i>Ludwig-Maximilians University of Munich</i>  Cristina Suárez Rodríguez, Sr., MD, PhD <i>Vall d'Hebron University Hospital</i>
	<b>Living with RCC – Long Term Survival and Frustration</b>	Theresa Junker, PhD <i>Research and Innovation Unit of Radiology</i>
	<b>Supplements and Concomitant Drugs: Interactions, Efficacy</b>	Dora Niedersüß-Beke, MD, MBA <i>Klinik Ottakring</i>
	<b>Patients Trust in Care</b>	Dena Battle <i>KCCure</i>
	<b>Quality of Life – What is That and How Can We Optimize it?</b>	David Cella, PhD <i>Northwestern University/Feinberg School of Medicine</i>
	<b>Rare Subtypes – A Patients Tale</b>	Per Larsen <i>Retired Chief Police Inspector at the Copenhagen Police</i>
	<b>Session 3 Panel Discussion and Q&amp;A</b>	All Speakers
12:45–14:15	<b>Posters and Lunch</b> <b>LENNOX 1</b>	

## Program Agenda • Friday, 21 April 2023

14:15–15:15	<b>Session 4: Oral Abstracts</b> <b>LENNOX 3</b>	Gabriel Malouf, MD, PhD <i>Institut de Cancérologie de Strasbourg-Europe, Strasbourg University</i>  Lars Lund, MD, PhD <i>University of Southern Denmark</i>
	<b>Abstract 1:</b> Cross-trial Propensity Score Weighted Analysis of Nivolumab Plus Ipilimumab Versus Nivolumab Monotherapy for Patients with Untreated Advanced Renal Cell Carcinoma	Michael B. Atkins, MD <i>Georgetown Lombardi Comprehensive Cancer Center</i>
	<b>Abstract 2:</b> Health Related Quality of Life (HR-QOL) Measures in Renal Cell Carcinoma: Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30 and EQ-5D	Benjamin D. Mercier, BS <i>City of Hope Comprehensive Cancer Center</i>
	<b>Abstract 3:</b> Patients' Experiences on the Course of Treatment After Partial Nephrectomy or Percutaneous Cryoablation of Small Renal Cell Carcinoma - A Cross-Sectional Multicenter Study	Theresa Junker, PhD <i>Research and Innovation Unit of Radiology</i>
	<b>Abstract 4:</b> Eosinophilic Solid and Cystic Renal Cell Carcinoma: A Rare New Entity Associated with TSC1/TSC2 Genetic Alteration and Rare Metastatic Potential	Virginie Verkarre <i>APHP-Centre, Université de Paris-Cité,</i>
	<b>Abstract 5:</b> Baseline Circulating Soluble Factors as Predictors of Benefit from Nivolumab in Metastatic Renal Cell Carcinoma (mRCC): Additional Multivariate Analyses of the Pooled Translational NIVOREN GETUG-AFU26 Population	Lucia Carril Ajuria <i>Institute Gustave Roussy/ CHU Brugmann-CHU Saint-Pierre</i>
	<b>Session 4 Q&amp;A</b>	
15:15–15:30	<b>Break</b> <b>LENNOX 1</b>	

## Program Agenda • Friday, 21 April 2023

15:30-16:30	<b>Session 5: First Line Therapy Debates</b> <b>LENNOX 3</b>	Viktor Gruenwald, MD PhD <i>Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology and Clinical for Urology, Essen, Germany</i>  Lisa Pickering, MD, PhD <i>The Royal Marsden NHS Foundation Trust</i>
	<b>Debate: In favour of IO-TKI Triplets</b>	Laurence Albiges, MD, PhD <i>Institut Gustave Roussy</i>  Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>
	<b>Debate: In Favour of IO-IO</b>	Michael B. Atkins, MD <i>Georgetown Lombardi Comprehensive Cancer Center</i>
	<b>Optimal Toxicity Management</b>	Kate Young, MBBS, MA, MRCP, MD(Res) <i>Royal Marsden Hospital</i>
	<b>Illustrative Clinical Scenarios</b>	Lisa Pickering, MD, PhD <i>The Royal Marsden NHS Foundation Trust</i>
	<b>Session 5 Panel Discussion and Q&amp;A</b>	
17:05–17:50	<b>Keynote 2: John Fitzpatrick Award Lecture</b> <b>LENNOX 3</b>	Arnaud Méjean, HEGP, APHP <i>Université Paris-Centre</i>
17:05 - 17:50	<b>Women in RCC</b> Sponsored by Eisai <b>LENNOX 2</b>	Laurence Albiges, MD, PhD <i>Institut Gustave Roussy</i>  Lisa Pickering, MD, PhD <i>The Royal Marsden NHS Foundation Trust</i>
17:00–18:30	<b>KCA Reception</b> <b>LENNOX 1</b>	
18:00–18:30	<b>Poster Walk</b> <b>LENNOX 1</b>	Ignacio Duran, MD PhD <i>Medical Oncology Department, Hospital Universitario Marques de Valdecilla</i>  Timothy O'Brien, MA, DM, FRCS (Urol) <i>Guy's and St. Thomas' NHS Foundation Trust</i>

## Program Agenda • Saturday, 22 April 2023

8:30–9:00	<b>Welcome Session and Session 6: KCA Updates</b> <b>LENNOX 3</b>	Daniel J. George, MD <i>Duke University Medical Center</i>  Dora Niedersüß-Beke, MD, MBA <i>Klinik Ottakring</i>
	<b>KCA Updates</b>	Laurence Albiges, MD, PhD <i>Institut Gustave Roussy</i>
	<b>Keynote 3: Christopher G. Wood Rising Star Award Lecture</b>	Sarah Psutka, MD MS <i>University of Washington</i>
	<b>Session 6 Q&amp;A</b>	
9:00–10:00	<b>Session 7: Beyond First Line Therapy</b> <b>LENNOX 3</b>	Laurence Albiges, MD, PhD <i>Institut Gustave Roussy</i>  Daniel J. George, MD <i>Duke University Medical Center</i>
	<b>Beyond First Line Therapy: Selecting Further Lines of Therapies After IO-IO</b>	Ulka N. Vaishampayan, MD <i>University of Michigan</i>
	<b>Beyond First Line Therapy: Selecting Further Lines of Therapies After IO-TKI</b>	Ignacio Duran, MD PhD <i>Medical Oncology Department, Hospital Universitario Marques de Valdecilla</i>
	<b>Integrating Predictive Biomarkers into Therapy Selection</b>	Gabriel Malouf, MD, PhD <i>Institut de Cancérologie de Strasbourg-Europe, Strasbourg University</i>
	<b>Optimizing Later Line Therapy Selection</b>	Camillo Porta <i>University of Bari “A. Moro”</i>
	<b>Session 7 Q&amp;A</b>	

## Program Agenda • Saturday, 22 April 2023

10:00–11:00	<b>Session 8 – Management of RCC</b> <b>LENNOX 3</b>	Sylvie Negrier, MD PhD <i>Centre Leon Bérard, Lyon I University</i>
		Ulka N. Vaishampayan, MD <i>University of Michigan</i>
	<b>Future Radiotherapy Options</b>	Andrew Z. Wang, MD <i>University of Texas Southwestern Medical Center</i>
	<b>Developments in Radiation Therapy in RCC</b>	Giulia Marvaso <i>Istituto Europeo di Oncologia</i>
	<b>Prognostication in RCC</b>	Daniel Heng, BSc, MD, MPH, FRCPC, MSC <i>Tom Baker Cancer Centre</i>
	<b>Diagnostic and Therapeutic Imaging in RCC</b>	Sophie Carina Kunte, B. Sc. <i>Ludwig-Maximilians University of Munich</i>
	<b>Session 8 Q&amp;A</b>	
11:00–11:10	<b>Break</b> <b>LENNOX 1</b>	
11:10–12:10	<b>Session 9: Progress in the Treatment of Variant Histology RCC</b> <b>LENNOX 3</b>	Cristina Suárez Rodríguez, Sr., MD, PhD <i>Vall d'Hebron University Hospital</i>
		Michael B. Atkins, MD <i>Georgetown Lombardi Comprehensive Cancer Center</i>
	<b>Papillary RCC</b>	Manuela Schmidinger, MD <i>Medical University of Vienna, Austria</i>
	<b>Chromophobe RCC</b>	Stéphane Oudard, PhD, MD <i>Georges Pompidou Hospital</i>
	<b>Collecting Duct and Renal Medullary Carcinoma</b>	Giuseppe Procopio, MD <i>Fondazione IRCCS Istituto Nazionale Tumori</i>
	<b>HLRCC and Translocation RCC</b>	Nizar M. Tannir, MD FACP <i>University of Texas MD Anderson Cancer Center</i>
	<b>Session 9 Q&amp;A</b>	

## Program Agenda • Saturday, 22 April 2023

12:10–13:40	<b>Posters and Lunch</b> <b>LENNOX 1</b>	
12:30–13:30	<b>Industry Session: Recent Advances in the Management of Renal Cell Carcinoma</b> Sponsored by Merck, Sharp & Dohme <b>LAMMERMUIR 1 &amp; 2</b>	<p>Professor Thomas Powles Medical Oncologist Queen Mary University of London Barts Cancer Institute London, UK</p> <p>Professor Viktor Grünwald Medical Oncologist University Hospital Essen Essen, Germany</p>
13:40–14:40	<b>Session 10: Basic Science Integrated into Therapeutic Management</b> <b>LENNOX 3</b>	<p>Annika Fendler, PhD Charité - University Hospital</p> <p>Elizabeth (Lisa) Henske, MD Brigham and Women's Hospital, Harvard Medical School</p>
	<b>TLS and B-cell Responses in RCC</b>	Florent Petitprez, MD University of Edinburgh
	<b>Circulating T Cell Activation as Predictor of Therapy Response</b>	Haydn Kissick Emory University
	<b>Patient-derived Organotypic Cultures Predict Immunotherapy Responses</b>	Marieta Toma, MD Institute of Pathology, University Hospital Bonn
	<b>Transcriptomic Heterogeneity in RCC</b>	Annika Fendler, PhD Charité - University Hospital
	<b>Optimizing Clinical Trial Designs by Integrating Tissue Derived Markers</b>	Yann-Alexandre Vano Department of Medical Oncology, Georges Pompidou European Hospital, Paris
	<b>Session 10 Q&amp;A</b>	

## Program Agenda • Saturday, 22 April 2023

14:40–15:35	<b>Session 11: Special Topics</b> <b>LENNOX 3</b>	Sylvie Negrier, MD PhD <i>Centre Leon Bérard, Lyon I University</i>  Nizar M. Tannir, MD FACP <i>University of Texas MD Anderson Cancer Center</i>
	<b>Modulating Gut Microbiome to Influence Outcomes with IO</b>	Nazli Dizman, MD <i>Yale New Haven Hospital</i>
	<b>HIF2a in VHL and Beyond</b>	Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>
	<b>Novel Therapeutics *Except HiF2</b>	Thomas Powles, MBBS, MRCP, MD <i>Barts Cancer Institute</i>
	<b>Therapy of Patients with and of Brain Metastases</b>	Sylvie Negrier, MD PhD <i>Centre Leon Bérard, Lyon I University</i>
	<b>Session 11 Q&amp;A</b>	
15:35–15:45	<b>Poster Award Presentation</b> <b>LENNOX 3</b>	Lisa Pickering, MD, PhD <i>The Royal Marsden NHS Foundation Trust</i>  Lars Lund, MD, PhD <i>University of Southern Denmark</i>
15:45–16:50	<b>WoodFire®</b> <b>LENNOX 3</b>	Michael D. Staehler, MD, PhD <i>Ludwig-Maximilians University of Munich</i>  <b>WoodFire Panalists:</b> Bradley C. Leibovich, MD <i>Mayo Clinic</i> Thomas Powles, MBBS, MRCP, MD <i>Barts Cancer Institute</i> Ulka N. Vaishampayan, MD <i>University of Michigan</i> Arnaud Mejean, MD, PhD, HEGP, APHP <i>Université Paris-Centre</i>
16:50–17:00	<b>Session Closing</b> <b>LENNOX 3</b>	Michael D. Staehler, MD, PhD <i>Ludwig-Maximilians University of Munich</i>  Gabriel Malouf, MD, PhD <i>Institut de Cancérologie de Strasbourg-Europe, Strasbourg University</i>

## POSTER LISTINGS

<b>POSTER BY TOPIC</b>	<b>BOARD #</b>
Late-breaking Data Abstracts	A1
Regular Abstracts	A2–E5
Case Abstracts	E6–F2
Trials in Progress Abstracts	F3
Basic Science	A2, A3, A4
Diagnostics	A5
Imaging	A6
Patient-reported Outcomes	B1–B3
Quality of Care and Quality Improvement	B4
Real-World Evidence	B5–B6, C1–C6, D1–D3
Survivorship	E6, F1
Treatment Toxicities and Symptom Management	D4–D5
Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)	D6, E1, E2
Therapeutics- Local (Primary and Metastases)	E3
Tumor Biology, Biomarkers, and Pathology	E4–E5
Other	F3




POSTER # TOPIC	TITLE	PRESENTER
<b>Late-breaking Data Submission Abstract</b>		
A1 / Abstract 6 Topic: Other	2022 Global Patient Survey: Reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas	Rachel Giles
<b>Regular Abstract</b>		
A2 / Abstract 7 Topic: Basic Science	Circulating B cells subpopulations and outcomes to Checkpoint Blockade in patients with renal cell carcinoma	Marcus Teixeira
A3 / Abstract 8 Topic: Basic Science	Understand the Biology of Kidney Cancer Progression	Samy Lewiz-Habib
A4 / Abstract 9 Topic: Basic Science	Characterisation of HIF-mediated genoprotection in clear cell renal cell carcinoma	Sameh Elbadry
A5 / Abstract 10 Topic: Diagnostics	The use of Renal tumor biopsies (RBx) has increased at Haukeland University Hospital (HUS) during 2008-2022	Karin Hjelle
A6 / Abstract 11 Topic: Imaging	Correlation of PSMA expression on [18F]PSMA-1007 PET with morphological changes in patients with metastatic renal cell cancer undergoing tyrosine kinase and checkpoint inhibitor therapy	Sophie Carina Kunte
B1 / Abstract 12 Topic: Patient-reported Outcomes	T-Rex Study: Real-world evidence and patient-reported outcomes of mRCC patients treated first-line with tivozanib	Viktor Gruenwald
B2 / Abstract 13 Topic: Patient-reported Outcomes	Active Surveillance for Small Renal Masses: Living with a potential untreated cancer	Rasmine Bak
B3 / Abstract 14 Topic: Patient-reported Outcomes	Exploring the perspectives of patients with localised kidney cancer on their treatment decisions: a qualitative study	Katharina Beyer
B4 / Abstract 15 Topic: Quality of Care and Quality Improvement	Patient experience of follow-up after surgery for kidney cancer: a focus group study	Hannah Harrison

POSTER # TOPIC	TITLE	PRESENTER
B5 / Abstract 16 Topic: Real-World Evidence	Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data	Nessn Azawi
B6 / Abstract 17 Topic: Real-World Evidence	Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England	Prantik Das
C1 / Abstract 18 Topic: Real-World Evidence	Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)	Charlotte Toms
C2 / Abstract 19 Topic: Real-World Evidence	Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)	Azhar Malik
C3 / Abstract 20 Topic: Real-World Evidence	A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology	Paul Nathan
C4 / Abstract 21 Topic: Real-World Evidence	Real-world recurrence patterns in Danish renal cell carcinoma patients	Nessn Azawi
C5 / Abstract 22 Topic: Real-World Evidence	Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy	Balaji Venugopal
C6 / Abstract 23 Topic: Real-World Evidence	Role of cytoreductive nephrectomy in metastatic RCC, single institution	Ahmed Shaheen
D1 / Abstract 24 Topic: Real-World Evidence	Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France	Yann-Alexandre Vano
D2 / Abstract 25 Topic: Real-World Evidence	4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes	Kathryn Humphries

POSTER # TOPIC	TITLE	PRESENTER
D3 / Abstract 26 Topic: Real-World Evidence	Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution	Karen Marie Albrecht Olesen
D4 / Abstract 27 Topic: Treatment Toxicities and Symptom Management	Immune-related adverse events after $\geq 12$ months of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma	Agne Jovaisaite
D5 / Abstract 28 Topic: Treatment Toxicities and Symptom Management	Real world experience of managing immunotherapy toxicity at a UK tertiary centre	Chandan Sanghera
D6 / Abstract 29 Topic: Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)	Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: a retrospective multicentric study	Edwige Baudry
E1 / Abstract 30 Topic: Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)	Association of ABO blood type with toxicity and response to immunotherapy in metastatic renal cell carcinoma (mRCC)	Yishen Wang
E2 / Abstract 31 Topic: Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)	Efficacy of immune checkpoint inhibitor (ICI) combination therapy as first-line (1L) treatment in metastatic renal cell carcinoma (mRCC)	Nikita Tripathi
E3 / Abstract 32 Topic: Therapeutics- Local (Primary and Metastases)	Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial	Viktor Gruenwald
E4 / Abstract 33 Topic: Tumor Biology, Biomarkers, and Pathology	Investigating response to Axitinib in Kidney Cancer with Venous Tumour Thrombus: translational analysis of the NAXIVA Trial	James Jones

POSTER # TOPIC	TITLE	PRESENTER
E5 / Abstract 34 Tumor Biology, Biomarkers, and Pathology	Baseline cytokine levels according to IMDC score in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the NIVOREN GETUG-AFU 26 Translational study	Larissa Rainho
<b>Case Reports</b>		
E6 / Abstract 35 Topic: Survivorship	Renal cell carcinoma and therapeutic opportunities in the paradigm shift – a case report	Ana Vaz-Ferreira
F1 / Abstract 36 Topic: Survivorship	Long survivorship in metastatic kidney cancer during targeted-therapy era	José Brito da Silva
F2 / Abstract 37 Topic: Tumor Biology, Biomarkers, and Pathology	The metanephric adenoma - a benign variant of the Wilms' tumor: case report of an extremely rare kidney tumor	Andreas Bannowsky
<b>Trials in Progress</b>		
F3 / Abstract 38 Topic: Other	REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II trial testing reduced intensity immunotherapy across different cancers	Sophie Merick



**KIDNEY CANCER ASSOCIATION'S  
DATA FEDERATION**  
POWERED BY THE KCA THINK TANK

A new way to do multi-institutional research.  
Visit the Kidney Cancer Association booth  
to learn more.

# 2023 IKCS: Europe is Made Possible with the Generous Support of:

## PREMIER SPONSOR



## ELITE SPONSORS



## SUPPORTING SPONSORS



---

**Bristol Myers Squibb**  
EXHIBIT BOOTH #A1

**EUSAPharma**  
EXHIBIT BOOTH #B2

**Telix Pharma**  
EXHIBIT BOOTH #A2

**Kidney Cancer Association**  
EXHIBIT BOOTH #B1



**KidneyCancerAssociation®**

The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

**KIDNEYCANCER.ORG**

**office@kidneycancer.org | 800-850-9132**

**International: +1 847 332 1051**

**MAILING ADDRESS**

2777 Allen Parkway, Suite 424

Houston, TX 77019

**DONATION ADDRESS**

PO Box 676226

Dallas, TX 75267-6226

**HQ IN HOUSTON TEXAS**

**@KidneyCancer | #UnstoppableTogether**

